Prior to this, AstraZeneca reported positive results from the efzimfotase alfa Phase III clinical trial programme for ...

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZeneca's most important ...

AstraZeneca is driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly ...

Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients’ symptoms worsened, ...

Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...

By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...

April 2 (Reuters) - AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant ...

View AstraZeneca PLC AZN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...

AstraZeneca partners with Telangana to implement AI-driven lung cancer screening in public health facilities, enhancing early ...